Last reviewed · How we verify
GamEvac-Combi (vaccine)
GamEvac-Combi is a combination vaccine that stimulates immune responses against tick-borne encephalitis and Lyme disease through viral antigens.
GamEvac-Combi is a combination vaccine that stimulates immune responses against tick-borne encephalitis and Lyme disease through viral antigens. Used for Prevention of tick-borne encephalitis, Prevention of Lyme disease (Borreliosis).
At a glance
| Generic name | GamEvac-Combi (vaccine) |
|---|---|
| Sponsor | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation |
| Drug class | Combination inactivated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated tick-borne encephalitis virus and Borrelia burgdorferi (Lyme disease) antigens that trigger both humoral and cellular immune responses. This dual-antigen approach provides protection against the two most common tick-borne infections in Eastern Europe and Russia.
Approved indications
- Prevention of tick-borne encephalitis
- Prevention of Lyme disease (Borreliosis)
Common side effects
- Local injection site reactions (pain, erythema, swelling)
- Fever
- Myalgia
- Headache
Key clinical trials
- International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi (PHASE4)
- Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: